Apply to trial NCT06962254

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

Imatinib and Trametinib for KRAS-mutated Solid Tumor

In this pilot trial, participants with unresectable solid cancers harboring KRAS mutations will be provided with a compassionate treatment if their diseases progress after current standard treatments, or there is no available standard treatment. This trial will evaluate the efficacy and safety of the combination of trametinib and imatinib on chemotherapy refractory solid cancers.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Imatinib and Trametinib for KRAS-mutated Solid Tumor

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening